These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30507186)

  • 61. Homoharringtonine deregulates
    Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target.
    Zhang S; Zhang Q; Shi G; Yin J
    Biomed Pharmacother; 2018 Jan; 97():1189-1194. PubMed ID: 29136958
    [TBL] [Abstract][Full Text] [Related]  

  • 64. OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis.
    Bai LY; Weng JR; Chiu CF; Wu CY; Yeh SP; Sargeant AM; Lin PH; Liao YM
    Biochem Pharmacol; 2013 Nov; 86(10):1430-40. PubMed ID: 24041743
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia.
    Cole SR; Aylett GW; Harvey NL; Cambareri AC; Ashman LK
    Leukemia; 1996 Feb; 10(2):288-96. PubMed ID: 8637238
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
    Xu L; Zhang Y; Gao M; Wang G; Fu Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
    Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
    Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nobiletin Induces Protective Autophagy Accompanied by ER-Stress Mediated Apoptosis in Human Gastric Cancer SNU-16 Cells.
    Moon JY; Cho SK
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27428937
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.
    Liu L; Zhang J; Zhang X; Cheng P; Liu L; Huang Q; Liu H; Ren S; Wei P; Wang C; Dou C; Chen L; Liu X; Zhang H; Chen M
    J Mol Med (Berl); 2021 Jan; 99(1):107-118. PubMed ID: 33128580
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relative receptor tyrosine kinases and anti-apoptotic transcripts hold potential for predicting inferior outcome in adult acute myeloid leukemia: a prospective pilot study.
    Sharawat SK; Vishnubhatla S; Bakhshi R; Raina V; Kumar L; Sharma A; Bakhshi S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):501-508.e2. PubMed ID: 25065779
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
    Katagiri S; Chi S; Minami Y; Fukushima K; Shibayama H; Hosono N; Yamauchi T; Morishita T; Kondo T; Yanada M; Yamamoto K; Kuroda J; Usuki K; Akahane D; Gotoh A
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563085
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Transforming growth factor-beta 1 interferes with the proliferation-inducing activity of stem cell factor in myelogenous leukemia blasts through functional down-regulation of the c-kit proto-oncogene product.
    de Vos S; Brach MA; Asano Y; Ludwig WD; Bettelheim P; Gruss HJ; Herrmann F
    Cancer Res; 1993 Aug; 53(15):3638-42. PubMed ID: 7687925
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antiproliferative and apoptosis-inducing activity of nobiletin against three subtypes of human breast cancer cell lines.
    Chen C; Ono M; Takeshima M; Nakano S
    Anticancer Res; 2014 Apr; 34(4):1785-92. PubMed ID: 24692711
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.
    Advani AS
    Curr Hematol Malig Rep; 2006 Jun; 1(2):101-7. PubMed ID: 20425339
    [TBL] [Abstract][Full Text] [Related]  

  • 76. BCL7A inhibits the progression and drug-resistance in acute myeloid leukemia.
    Li T; Gao R; Xu K; Pan P; Chen C; Wang D; Zhang K; Qiao J; Gu Y
    Drug Resist Updat; 2024 Sep; 76():101120. PubMed ID: 39053383
    [TBL] [Abstract][Full Text] [Related]  

  • 77. IL1RAP potentiates multiple oncogenic signaling pathways in AML.
    Mitchell K; Barreyro L; Todorova TI; Taylor SJ; Antony-Debré I; Narayanagari SR; Carvajal LA; Leite J; Piperdi Z; Pendurti G; Mantzaris I; Paietta E; Verma A; Gritsman K; Steidl U
    J Exp Med; 2018 Jun; 215(6):1709-1727. PubMed ID: 29773641
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of HOXA9 Inhibitor DB818 on the Growth of Acute Myeloid Leukaemia Cells.
    Sonoda Y; Itoh M; Tohda S
    Anticancer Res; 2021 Apr; 41(4):1841-1847. PubMed ID: 33813389
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity.
    Grønningsæter IS; Reikvam H; Aasebø E; Bartaula-Brevik S; Tvedt TH; Bruserud Ø; Hatfield KJ
    Cells; 2020 May; 9(5):. PubMed ID: 32392896
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nontoxic-dose of deguelin induce NPMc+ AML cell differentiation by selectively targeting Mt NPM1/SIRT1 instead of HDAC1/3.
    Wang YP; Yi S; Wen L; Zhang BP; Zhao Z; Hu JY; Zhao F; He J; Fang J; Zhang C; Cui G; Chen Y
    Curr Cancer Drug Targets; 2014; 14(8):685-99. PubMed ID: 25348016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.